AMGN

Business Context and Reporting Period

Company: Amgen Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2008
Business Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Principal products include Aranesp, EPOGEN, Neulasta, NEUPOGEN, and ENBREL. The company operates in a single segment: human therapeutics.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Total revenues increased 1% for the three months and decreased 1% for the six months ended June 30, 2008, compared to the prior year. Excluding favorable foreign exchange impacts, product sales were relatively unchanged for the quarter and declined 1% for the six-month period.
• Product Performance:
  • Aranesp: Sales declined 13% (QTD) and 19% (YTD) due to regulatory and reimbursement developments affecting erythropoiesis-stimulating agents (ESAs), particularly in the U.S. supportive cancer care setting.
  • Neulasta/NEUPOGEN: Sales increased 15% (QTD) and 11% (YTD) driven by increased demand.
  • ENBREL: Sales increased 2% (QTD) and 15% (YTD), aided by a shift to a wholesaler distribution model.
• Expenses:
  • Cost of Sales: Decreased 8% for both periods, driven by lower ENBREL costs and reduced inventory reserves.
  • R&D: Decreased 1% (QTD) and 10% (YTD) due to restructuring savings and lower clinical trial costs, partially offset by a $100 million upfront payment for a collaboration with Kyowa Hakko.
  • SG&A: Increased 5% (QTD) and 9% (YTD), primarily due to higher profit share expenses paid to co-promotion partner Wyeth.
• Restructuring: The company has incurred $773 million of the estimated $775 million to $825 million in restructuring charges as of June 30, 2008.

Guidance, Outlook, and Risks

• Regulatory & Reimbursement Risks: Significant headwinds persist for ESA products (Aranesp, EPOGEN) due to FDA label changes, CMS reimbursement restrictions (Decision Memorandum), and European Commission labeling updates. These factors have materially reduced demand and may continue to impact sales.
• Legal Proceedings: Amgen settled antitrust litigation with Ortho Biotech for $200 million. Other significant contingencies include Average Wholesale Price (AWP) litigation, patent disputes with Roche regarding MIRCERA, and generic infringement suits regarding Sensipar.
• Accounting Changes: The company expects the adoption of FSP APB 14-1 in Q1 2009 to have a material adverse impact on reported net income due to the bifurcation of convertible debt, though it will not affect cash flows.
• Liquidity: The company maintains strong liquidity with $8.5 billion in cash, cash equivalents, and marketable securities. Approximately $5.9 billion is held in foreign jurisdictions and would incur U.S. taxes if repatriated.
• Capital Allocation: The company repurchased 32.7 million shares for $1.5 billion in the first six months of 2008. $4.9 billion remains available for stock repurchases.

Investor Verification Checklist

• ESA Sales Trajectory: Verify the extent of the decline in Aranesp and EPOGEN sales and the potential for further erosion due to ongoing CMS and FDA regulatory actions.
• Restructuring Completion: Confirm the finalization of the $775M-$825M restructuring plan and the realization of anticipated cost savings.
• Legal Settlements: Monitor the status of the AWP litigation and the outcome of the Roche patent dispute regarding MIRCERA.
• Convertible Debt Accounting: Assess the projected impact of the upcoming FSP APB 14-1 adoption on future reported earnings.
• Product Pipeline: Review the status of late-stage candidates, specifically denosumab (osteoporosis) and Nplate (ITP), and their regulatory approval timelines.